Literature DB >> 1696855

Prostatic acid phosphatase in serum of patients with prostatic cancer is a specific phosphotyrosine acid phosphatase.

L Nguyen1, A Chapdelaine, S Chevalier.   

Abstract

We developed an assay to measure at acid pH the phosphotyrosine phosphatase activity in sera from patients with prostatic cancer. The method used quantifies the inorganic phosphate liberated from phosphotyrosine after incubation with serum, followed by the deproteinization of the reaction mixture. A high acid phosphatase (EC 3.1.3.2) activity towards phosphotyrosine was observed in all sera from patients with increased activity of prostatic acid phosphatase. This activity represented 96% of prostatic acid phosphatase and 77% of total acid phosphatase activities. Moreover, it was correlated (r = 0.91) with the amount of serum prostatic acid phosphatase determined by radioimmunoassay. When serum acid phosphatase activity was measured on several phosphorylated substrates, preferential hydrolysis was demonstrated for those in which the phosphate group was esterified on an aromatic ring rather than those presenting an aliphatic chain. Among phosphoamino acids, only phosphotyrosine was a good substrate, with little or no activity observed with phosphoserine and phosphothreonine. Human seminal plasma and partially purified prostatic acid phosphatase, tested for their activity on some of these substrates, gave similar results. On the other hand, sera from patients with above-normal alkaline phosphatase activity and no prostatic disease showed little or no activity on phosphotyrosine at both acid and alkaline pH values. Evidence is presented that the prostatic acid phosphatase in serum is a specific phosphotyrosine acid phosphatase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696855

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  The enhancement by pervanadate of tyrosine phosphorylation on prostatic proteins occurs through the inhibition of membrane-associated tyrosine phosphatases.

Authors:  M Boissonneault; A Chapdelaine; S Chevalier
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

2.  Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.

Authors:  C Liebow; M T Lee; A R Kamer; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

3.  Rat acid phosphatase: overexpression of active, secreted enzyme by recombinant baculovirus-infected insect cells, molecular properties, and crystallization.

Authors:  P Vihko; R Kurkela; K Porvari; A Herrala; A Lindfors; Y Lindqvist; G Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

4.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

5.  Prostatic-like acid phosphatase in human endometrial glands and its cyclic activity.

Authors:  Seppo Edvin Partanen
Journal:  J Mol Histol       Date:  2007-10-12       Impact factor: 2.611

6.  Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.

Authors:  Shahana Sarwar; Mohammed Abdul Majid Adil; Parveen Nyamath; Mohammed Ishaq
Journal:  Prostate Cancer       Date:  2017-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.